Original article published by Gabriel S. Gonçalves with the title "Urgent call for Data on the prophylactic use of Hydroxychloroquine for Covid-19"
- Post-exposure Prophylaxis/Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP, NCT04308668
- Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (NCT04304053)
- Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases